Literature DB >> 28175981

[Catheter ablation of ventricular extrasystoles and ventricular tachycardia in the elderly].

Philipp Halbfaß1,2, Karin Nentwich1, Kai Sonne1, Elena Ene1, Franziska Fochler1, Andreas Mügge3, Bernhard Schieffer2, Thomas Deneke4,5.   

Abstract

BACKGROUND: The prevalence of structural heart disease increases with higher age, and thereby the basis for ventricular arrhythmias is created. Catheter ablation has been shown to be an effective therapy option that is very safe and achieves good long-term results in patients with recurrent ventricular tachycardia (VT). Data regarding ablation in patients older than 75 years is sparse, although this patient group was included as a minority in most published VT ablation studies. Data from younger patient collectives may not be transferable to older patient cohorts due to differences in patient comorbidities and baseline characteristics.
METHODS: Studies with patient collectives ≥75 years or even ≥80 years show comparable efficacy of catheter ablation for VT; however, the complication rate is higher, mainly due to groin complications, increases. Catheter ablation of ischemic VT appears effective and safe even in ≥75 year olds; however, extensive data for other structural heart diseases are lacking. Epicardial procedures are also possible and safe in older patients (≥80 years). Due to the significant challenges of VT ablation in older patients, including the consideration of complex comorbidities, these should be performed in specialized centers with high expertise.
CONCLUSION: The aim of catheter ablation in older patients is, above all, to improve quality of life and morbidity. Long-term survival is significantly lower due to the "near end of life" situation than in younger patients. Careful consideration of alternative therapy options, chances for success of the catheter ablation, and their risks, taking into account specific patient conditions and symptoms, is crucial in these patients.

Entities:  

Keywords:  Catheter ablation; Efficacy; Quality of life; Safety; Ventricular tachycardia

Mesh:

Year:  2017        PMID: 28175981     DOI: 10.1007/s00399-017-0483-5

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  18 in total

1.  Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks.

Authors:  Eleanor B Schron; Derek V Exner; Qing Yao; Louise S Jenkins; Jonathan S Steinberg; James R Cook; Steven P Kutalek; Peter L Friedman; Rosemary S Bubien; Richard L Page; Judy Powell
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

2.  Gender and age differences in candidates for radiofrequency catheter ablation of idiopathic ventricular arrhythmias.

Authors:  Yasuaki Tanaka; Hiroshi Tada; Sachiko Ito; Shigeto Naito; Koji Higuchi; Koji Kumagai; Hitoshi Hachiya; Kenzo Hirao; Shigeru Oshima; Koichi Taniguchi; Kazutaka Aonuma; Mitsuaki Isobe
Journal:  Circ J       Date:  2011-05-12       Impact factor: 2.993

3.  Efficacy and safety of catheter ablation in octogenarians.

Authors:  E S Zado; D J Callans; C D Gottlieb; S P Kutalek; S L Wilbur; F L Samuels; S E Hessen; C M Movsowitz; J M Fontaine; S E Kimmel; F E Marchlinski
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

4.  Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Authors:  Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

5.  Effectiveness of catheter ablation of ventricular tachycardia in elderly patients with structural heart disease.

Authors:  Ana Viana-Tejedor; José L Merino; Armando Pérez-Silva; Rocío Cózar León; Sara Moreno Reviriego; Eva Díaz Caraballo; Rafael Peinado Peinado; José L López-Sendón
Journal:  Rev Esp Cardiol       Date:  2010-02       Impact factor: 4.753

6.  Novel ECG predictor of difficult cases of outflow tract ventricular tachycardia: peak deflection index on an inferior lead.

Authors:  Hitoshi Hachiya; Kenzo Hirao; Takeshi Sasaki; Koji Higuchi; Tatsuya Hayashi; Yasuaki Tanaka; Mihoko Kawabata; Mitsuaki Isobe
Journal:  Circ J       Date:  2009-12-14       Impact factor: 2.993

7.  Prophylactic catheter ablation for the prevention of defibrillator therapy.

Authors:  Vivek Y Reddy; Matthew R Reynolds; Petr Neuzil; Allison W Richardson; Milos Taborsky; Krit Jongnarangsin; Stepan Kralovec; Lucie Sediva; Jeremy N Ruskin; Mark E Josephson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

8.  Implantable cardioverter-defibrillator prescription in the elderly.

Authors:  Andrew E Epstein; G Neal Kay; Vance J Plumb; H Thomas McElderry; Harish Doppalapudi; Takumi Yamada; Jeff Shafiroff; Zaffer A Syed; Sergio Shkurovich
Journal:  Heart Rhythm       Date:  2009-04-10       Impact factor: 6.343

9.  Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial.

Authors:  Karl-Heinz Kuck; Anselm Schaumann; Lars Eckardt; Stephan Willems; Rodolfo Ventura; Etienne Delacrétaz; Heinz-Friedrich Pitschner; Josef Kautzner; Burghard Schumacher; Peter S Hansen
Journal:  Lancet       Date:  2010-01-02       Impact factor: 79.321

10.  Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease.

Authors:  Keiichi Inada; Kurt C Roberts-Thomson; Jens Seiler; Daniel Steven; Usha B Tedrow; Bruce A Koplan; William G Stevenson
Journal:  Heart Rhythm       Date:  2010-02-16       Impact factor: 6.343

View more
  1 in total

Review 1.  [Current strategies in the treatment of ventricular tachycardia by catheter ablation : A review].

Authors:  S Koenig; A Arya; G Hindricks; B Dinov
Journal:  Herz       Date:  2017-09-07       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.